BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

CStone's Sugemalimab Granted NMPA Approval for Esophageal Cancer

Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for use in combination with fluorouracil and platinum-based chemotherapy...

December 11, 2023 | News

Regor Reports Positive Results for RGT-419B in Advanced Breast Cancer After CDK4/6 Inhibitor and Endocrine Therapy

RGT-419B, a next generation CDK4 inhibitor, was safe and well tolerated in a First-in-Human Phase 1A single agent dose escalation s...

December 08, 2023 | News

FDA Prioritizes Review of PADCEV® Combo for Advanced Bladder Cancer

Results of pivotal confirmatory trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall survival and progres...

December 04, 2023 | News

Alecensa by Roche Cuts Risk in Asian ALK-Positive Lung Cancer Patients by Over 60%.

ALINA is the first and only Phase III study to show an improvement in disease-free survival in patients from Asia with early-stage resected ALK-posit...

December 04, 2023 | News

Clarity's theranostic prostate cancer trial progresses at the highest dose level cohort

Cohort 3 of the theranostic SECuRE trial investigating 64Cu/67Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has enrolled a...

November 30, 2023 | News

GE HealthCare Releases MyBreastAI Suite to Support Clinicians in Accelerating Breast Cancer Detection

GE HealthCare (Nasdaq: GEHC) announced the release of a new, all-in-one platform of artificial intelligence (AI) apps to support clinicians with breast can...

November 28, 2023 | News

Lunit's AI-Powered Mammography Analysis Solution Proves Comparable to Radiologists in Breast Cancer Detection

- A large population-based retrospective study in Denmark validates that Lunit INSIGHT MMG's accuracy is on par with tha...

November 27, 2023 | News

Pfizer and Astellas' XTANDI® Approved by U.S. FDA in Earlier Prostate Cancer Treatment Setting

Astellas Pharma Inc. announced that the companies received an approval by the U.S. Food and Drug Administration (FDA) of a supplemental New Drug Appl...

November 27, 2023 | News

Boehringer Ingelheim broadens immuno-oncology portfolio with T3 Pharma acquisition

Despite the significant transformation of the cancer treatment landscape by immunotherapies, long-term remissions only occur in 15-20% of cancer patients. ...

November 27, 2023 | News

BeiGene and Ensem Therapeutics Partner to Advance CDK2 Inhibitor

“We are committed to developing novel molecules with the potential to transform the therapeutic landscape for cancer patients, and this partnership f...

November 23, 2023 | News

Porton Advanced and Ascle Therapeutics Form Strategic Partnership for NK Cell Applications in Cancer Prevention, Beauty, and Anti-aging

Porton Advanced is committed to providing end-to-end gene and cell therapy CDMO services, covering fields such as plasmids, cell therapy, gene therapy, and...

November 21, 2023 | News

Foundation Medicine Collaborates with Pierre Fabre on Non-Small Cell Lung Cancer Diagnostics

The companies will work collaboratively to seek the regulatory approval for Foundation Medicine assays which detect mutations including BRAFV600E to i...

November 16, 2023 | News

SCG Cell Therapy's SCG101 Shows Promising Results in First-in-Human Trial for Advanced HBV-related Hepatocellular Carcinoma at AASLD Liver Meeting 2023

Results from a first-in-human clinical trial showed that SCG101 demonstrated promising antiviral and antitumor activities in patients with advanced HBV-rel...

November 14, 2023 | News

P&G's Gillette and Braun Join Forces with Movember to Tackle Men's Health Crisis in Australia

In Australia, one in five men will be diagnosed with prostate cancer in their lifetime. One man globally dies by suicide every minute. Testicular cancer is...

November 13, 2023 | News

Stay Connected